TDACU
TDACU
Translational Development Acquisition Corp.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $137.68K ▼ | $4.28M ▲ | $1.66M ▲ | 1.21K% ▲ | $0.08 ▲ | $-213.66K ▲ |
| Q2-2025 | $191.76K ▼ | $221.13K ▼ | $1.62M ▲ | 846.54% ▲ | $0.07 ▼ | $-221.13K ▲ |
| Q1-2025 | $223.85K ▲ | $347.41K ▲ | $1.48M ▲ | 662.53% ▲ | $0.37 ▲ | $-347.41K ▼ |
| Q4-2024 | $0 | $133.39K ▲ | $-8.04K ▲ | 0% | $-0 ▲ | $-135.07K ▼ |
| Q3-2024 | $0 | $61.28K | $-61.28K | 0% | $-0.02 | $-61.28K |
What's going well?
Net income and EPS improved slightly, and there are no interest or tax burdens. The company managed to report a profit despite a tough quarter.
What's concerning?
Revenue dropped sharply, costs are out of control, and the only reason for profit is a large one-off income. The underlying business is losing money and margins are negative.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $47.15K ▲ | $179.98M ▲ | $6.46M ▲ | $173.52M ▲ |
| Q2-2025 | $35.26K ▼ | $178.18M ▲ | $6.32M ▼ | $171.86M ▲ |
| Q1-2025 | $206.6K ▼ | $176.6M ▲ | $6.36M ▲ | $170.24M ▲ |
| Q4-2024 | $438.17K ▲ | $175M ▲ | $6.25M ▲ | $168.75M ▲ |
| Q3-2024 | $224.04K | $393.77K | $964.4K | $-570.63K |
What's financially strong about this company?
The company has almost no debt and a huge equity cushion, meaning it owes very little compared to what it owns. Book value is rising, and there are no hidden liabilities or off-balance-sheet risks.
What are the financial risks or weaknesses?
Cash is extremely low, with less than 20 cents in current assets for every $1 in near-term bills. The company has negative retained earnings, so it hasn't been profitable over its history, and asset quality is mixed with a large chunk in intangibles.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.66M ▲ | $-1.24M ▼ | $-2.1M ▼ | $8.58M ▲ | $11.89K ▲ | $-1.24M ▼ |
| Q2-2025 | $1.62M ▲ | $-171.34K ▼ | $0 ▲ | $0 ▼ | $-171.34K ▼ | $-171.34K ▲ |
| Q1-2025 | $1.48M ▲ | $924.9K ▲ | $-1.25M ▲ | $697.02K ▼ | $400.64K ▲ | $-231.57K ▲ |
| Q4-2024 | $-8.04K ▲ | $-810.96K ▼ | $-174.22M ▼ | $175.25M ▲ | $214.14K ▲ | $-810.96K ▼ |
| Q3-2024 | $-61.28K | $-40.48K | $0 | $192.5K | $152.02K | $-40.48K |
What's strong about this company's cash flow?
The company is still able to raise outside funding and pay out large dividends. Net income is positive, showing some underlying profitability on paper.
What are the cash flow concerns?
Cash flow from operations is deeply negative and getting worse. The company is paying out more in dividends than it generates in cash, and now depends on outside money to survive.
5-Year Trend Analysis
A comprehensive look at Translational Development Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.
TDACU has moved from a small, thinly capitalized SPAC to a much larger entity with stronger reported liquidity and positive equity. The income statement shows a dramatic step-up in activity and improved margins, while the balance sheet now reflects ample cash and an ability to meet short-term obligations. Management has demonstrated the capacity to raise significant capital and execute large, complex transactions or accounting restructurings. These elements provide financial flexibility and a platform from which a meaningful operating business could be built, depending on future choices.
At the same time, the financials are highly unusual and carry several important risks. Revenue and assets have exploded in a way that suggests one-off events rather than a stable business, with the balance sheet dominated by goodwill and other intangibles that could be written down if expectations are not met. Cash flow from operations and free cash flow are deeply negative, signaling that the company is not yet self-sustaining and remains dependent on external financing. As a SPAC or post-transaction shell, TDACU also faces deal risk, valuation risk on any target, potential shareholder dilution, regulatory scrutiny, and the possibility that the acquired business underperforms relative to the lofty values implied by the recent accounting changes. Data inconsistencies between the SPAC status and reported operating scale further increase uncertainty around the quality of these figures.
Looking ahead, TDACU’s trajectory will depend far more on strategic decisions and deal execution than on current period-to-period trends. The company now has a stronger balance sheet and liquidity, which gives it room to maneuver, but its income and cash flow statements show that true, cash-backed profitability has not yet been achieved. The outlook is therefore binary in nature: a successful business combination and integration could eventually convert today’s intangible-heavy balance sheet into a solid, cash-generating operation, while a poor or delayed deal could lead to write-downs, continued cash burn, and a reset of expectations. Until a clear, enduring operating business emerges, the reported numbers should be interpreted as transitional and subject to significant revision.
About Translational Development Acquisition Corp.
http://www.tridentacquisitions.comTrident Acquisitions Corp. is a shell company. The Company is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company focuses on identifying a business to a particular industry or geographic region of the world.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $137.68K ▼ | $4.28M ▲ | $1.66M ▲ | 1.21K% ▲ | $0.08 ▲ | $-213.66K ▲ |
| Q2-2025 | $191.76K ▼ | $221.13K ▼ | $1.62M ▲ | 846.54% ▲ | $0.07 ▼ | $-221.13K ▲ |
| Q1-2025 | $223.85K ▲ | $347.41K ▲ | $1.48M ▲ | 662.53% ▲ | $0.37 ▲ | $-347.41K ▼ |
| Q4-2024 | $0 | $133.39K ▲ | $-8.04K ▲ | 0% | $-0 ▲ | $-135.07K ▼ |
| Q3-2024 | $0 | $61.28K | $-61.28K | 0% | $-0.02 | $-61.28K |
What's going well?
Net income and EPS improved slightly, and there are no interest or tax burdens. The company managed to report a profit despite a tough quarter.
What's concerning?
Revenue dropped sharply, costs are out of control, and the only reason for profit is a large one-off income. The underlying business is losing money and margins are negative.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $47.15K ▲ | $179.98M ▲ | $6.46M ▲ | $173.52M ▲ |
| Q2-2025 | $35.26K ▼ | $178.18M ▲ | $6.32M ▼ | $171.86M ▲ |
| Q1-2025 | $206.6K ▼ | $176.6M ▲ | $6.36M ▲ | $170.24M ▲ |
| Q4-2024 | $438.17K ▲ | $175M ▲ | $6.25M ▲ | $168.75M ▲ |
| Q3-2024 | $224.04K | $393.77K | $964.4K | $-570.63K |
What's financially strong about this company?
The company has almost no debt and a huge equity cushion, meaning it owes very little compared to what it owns. Book value is rising, and there are no hidden liabilities or off-balance-sheet risks.
What are the financial risks or weaknesses?
Cash is extremely low, with less than 20 cents in current assets for every $1 in near-term bills. The company has negative retained earnings, so it hasn't been profitable over its history, and asset quality is mixed with a large chunk in intangibles.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.66M ▲ | $-1.24M ▼ | $-2.1M ▼ | $8.58M ▲ | $11.89K ▲ | $-1.24M ▼ |
| Q2-2025 | $1.62M ▲ | $-171.34K ▼ | $0 ▲ | $0 ▼ | $-171.34K ▼ | $-171.34K ▲ |
| Q1-2025 | $1.48M ▲ | $924.9K ▲ | $-1.25M ▲ | $697.02K ▼ | $400.64K ▲ | $-231.57K ▲ |
| Q4-2024 | $-8.04K ▲ | $-810.96K ▼ | $-174.22M ▼ | $175.25M ▲ | $214.14K ▲ | $-810.96K ▼ |
| Q3-2024 | $-61.28K | $-40.48K | $0 | $192.5K | $152.02K | $-40.48K |
What's strong about this company's cash flow?
The company is still able to raise outside funding and pay out large dividends. Net income is positive, showing some underlying profitability on paper.
What are the cash flow concerns?
Cash flow from operations is deeply negative and getting worse. The company is paying out more in dividends than it generates in cash, and now depends on outside money to survive.
5-Year Trend Analysis
A comprehensive look at Translational Development Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.
TDACU has moved from a small, thinly capitalized SPAC to a much larger entity with stronger reported liquidity and positive equity. The income statement shows a dramatic step-up in activity and improved margins, while the balance sheet now reflects ample cash and an ability to meet short-term obligations. Management has demonstrated the capacity to raise significant capital and execute large, complex transactions or accounting restructurings. These elements provide financial flexibility and a platform from which a meaningful operating business could be built, depending on future choices.
At the same time, the financials are highly unusual and carry several important risks. Revenue and assets have exploded in a way that suggests one-off events rather than a stable business, with the balance sheet dominated by goodwill and other intangibles that could be written down if expectations are not met. Cash flow from operations and free cash flow are deeply negative, signaling that the company is not yet self-sustaining and remains dependent on external financing. As a SPAC or post-transaction shell, TDACU also faces deal risk, valuation risk on any target, potential shareholder dilution, regulatory scrutiny, and the possibility that the acquired business underperforms relative to the lofty values implied by the recent accounting changes. Data inconsistencies between the SPAC status and reported operating scale further increase uncertainty around the quality of these figures.
Looking ahead, TDACU’s trajectory will depend far more on strategic decisions and deal execution than on current period-to-period trends. The company now has a stronger balance sheet and liquidity, which gives it room to maneuver, but its income and cash flow statements show that true, cash-backed profitability has not yet been achieved. The outlook is therefore binary in nature: a successful business combination and integration could eventually convert today’s intangible-heavy balance sheet into a solid, cash-generating operation, while a poor or delayed deal could lead to write-downs, continued cash burn, and a reset of expectations. Until a clear, enduring operating business emerges, the reported numbers should be interpreted as transitional and subject to significant revision.

CEO
Michael Hoffman

